ACM
UTHR icon

Argent Capital Management’s United Therapeutics UTHR Stock Holding History

Argent Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,530
Closed -$328K – 217
2017
Q2 		$328K Hold
2,530
– – 0.01% 188
2017
Q1 		$343K Buy
2,530
+60
+2% +$9.09K 0.01% 176
2016
Q4 		$354K Buy
2,470
+220
+10% +$28.1K 0.01% 174
2016
Q3 		$266K Buy
2,250
+200
+10% +$24K 0.01% 186
2016
Q2 		$217K Hold
2,050
– – 0.01% 196
2016
Q1 		$228K Hold
2,050
– – 0.01% 193
2015
Q4 		$321K Buy
+2,050
New +$298K 0.01% 170
2013
Q4 		– Sell
-34,875
Closed -$2.75M – 160
2013
Q3 		$2.75M Hold
34,875
– – 0.17% 78
2013
Q2 		$2.29M Buy
+34,875
New +$2.25M 0.15% 87

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Argent Capital Management's UTHR Position: Q3 2017 in Review

Argent Capital Management sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 2,530 shares — an estimated $328K sold.

Argent Capital Management first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $2.75M in Q3 2013. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Argent Capital Management reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Argent Capital Management sold 2,530 United Therapeutics shares in Q3 2017, an estimated $328K.
  • Argent Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
  • Argent Capital Management's United Therapeutics position peaked at $2.75M in Q3 2013.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Argent Capital Management's 13F filing for Q3 2017, filed 15 Nov 2017.